Medicinal nanocomposite and method of preparation thereof

Patent metadata

Field	Value
Publication number	US-11850260-B2
Application number	US-202217665014-A
Country	US
Kind code	B2
Filing date	Feb 4, 2022
Priority date	Feb 4, 2022
Publication date	Dec 26, 2023
Grant date	Dec 26, 2023

Abstract

A medicinal nanocomposite is provided. The medicinal nanocomposite includes 80 to 99 wt. % carrier particles of a porous silicate material selected from a group including mesoporous silica, silicalite, mesosilicalite, silver-incorporated silicalite, and silver- incorporated mesosilicalite, the carrier particles comprising a pore framework, 0.5 to 10 wt. % silver nanoparticles (Ag NPs) disposed on the pore framework, and 0.5 to 10 wt. % of a platinum-containing pharmaceutical compound disposed on at least one surface selected from an interior pore surface of the carrier particles, an exterior surface of the carrier particles, and a surface of the silver nanoparticles. The medicinal nanocomposite releases less than 10 mole % of the platinum-containing pharmaceutical compound after 60 to 84 hours at a pH of 4.5 to 7, based on an initial amount of the platinum-containing pharmaceutical compound present in the medicinal nanocomposite.

First claim

The invention claimed is:

1. A medicinal nanocomposite, comprising:
80 to 99 wt. % carrier particles of a porous silicate material selected from the group consisting of mesoporous silica, silicalite, mesosilicalite, silver-incorporated silicalite, and silver-incorporated mesosilicalite, the carrier particles comprising a pore framework;
0.5 to 10 wt. % silver nanoparticles (Ag NPs) dispersed on the pore framework, the silver nanoparticles being distinct from silver present in the silver-incorporated silicalite and/or silver-incorporated mesosilicalite; and
0.5 to 10 wt. % of a platinum-containing pharmaceutical compound disposed on at least one surface selected from an interior pore surface of the carrier particles, an exterior surface of the carrier particles, and a surface of the silver nanoparticles,
wherein the medicinal nanocomposite releases less than 10 mol. % of the platinum-containing pharmaceutical compound after 60 to 84 hours at a pH of 4.5, based on an initial amount of the platinum-containing pharmaceutical compound present in the medicinal nanocomposite.

2. The medicinal nanocomposite of claim 1 , wherein the carrier particles are particles of mesoporous silica which are substantially spherical and have a mean particle size of 50 to 110 nanometer (nm).

3. The medicinal nanocomposite of claim 1 , wherein the carrier particles are particles of mesoporous silica which are amorphous by PXRD.

4. The medicinal nanocomposite of claim 1 , wherein the carrier particles are porous silicate material selected from the group consisting of silicalite, mesosilicalite, silver-incorporated silicalite, and silver-incorporated mesosilicalite having a mean particle size of 25 to 400 nm.

5. The medicinal nanocomposite of claim 1 , wherein the carrier particles are particles of silver-incorporated mesosilicalite having a silicon to silver mole ratio of 10:1 to 150:1.

6. The medicinal nanocomposite of claim 1 , wherein the carrier particles are particles of silver-incorporated silicalite having a silicon to silver mole ratio of 10:1 to 150:1.

7. The medicinal nanocomposite of claim 1 , wherein the silver nanoparticles are disposed on the interior pore surface of the pore framework and/or an exterior surface of the pore framework and have a mean particle size of 5 to 50 nm.

8. The medicinal nanocomposite of claim 1 , wherein the silver nanoparticles are crystalline by PXRD.

9. The medicinal nanocomposite of claim 1 , wherein the platinum- containing pharmaceutical compound is at least one selected from the group consisting of cisplatin, oxaliplatin, and carboplatin.

10. The medicinal nanocomposite of claim 1 , wherein the medicinal nanocomposite has a mean pore size of 15 to 27.5 nm, a mean pore volume of 0.05 to 0.35 cubic centimeter per gram (cm 3 /g), and a mean surface are of 7.5-75-meter square per gram (m 2 /g).

11. A coated nanocomposite, comprising:
80 to 99 wt. % of the medicinal nanocomposite of claims 1 ; and
1 to 20 wt. % of a biocompatible coating comprising at least one selected from the group consisting of polyethylene glycol, polypropylene glycol, polylactic acid, polyvinyl alcohol, polyvinyl pyrrolidone, alginate, chitosan, dextran, and hyaluronic acid.

12. A method of forming the medicinal nanocomposite of claim 1 , the method comprising:
aging a reaction mixture comprising a silver source and particles of the porous silicate material in a first solvent for 4 to 24 hours to form an aged mixture;
heating the aged mixture to 90 to 150 degree Celsius (° C.) for 2 to 12 hours to form a first product;
calcining the first product at 350 to 650° C. for 1 to 6 hours to form a second product;
mixing the second product and the platinum-containing pharmaceutical compound in a second solvent for 2 to 12 hours at −15 to 15° C. to form the medicinal nanocomposite; and
isolating the medicinal nanocomposite.

13. The method of claim 12 , wherein the silver source is silver nitrate.

14. The method of claim 12 , wherein the first solvent is water and the second solvent is normal saline solution.

15. The method of claim 12 , wherein the porous silicate material is selected from the group consisting of silver-incorporated silicalite and silver-incorporated mesosilicalite and are prepared by:
adding a suspension of colloidal silica in the first solvent to a basic solution comprising 2 to 3 M hydroxide base to form a raw silicate solution;
aging the raw silicate solution for 1 to 30 minutes to form an aged silicate solution;
adding a silver source to the aged silicate solution to form a first reaction mixture;
aging the first reaction mixture to form an aged reaction mixture;
adding a template selected from the group consisting of tetrapropyl ammonium hydroxide and cetyltrimethyl ammonium bromide to form a templated solution;
stirring the templated solution for 0.5 to 3 hours to form a second reaction mixture;
hydrothermally treating the second reaction mixture at 125 to 195° C. for 24 to 120 hours to form a first precipitate; and
calcining the first precipitate at 400 to 750° C. for 2 to 12 hours to form the porous silicate material.

16. The method of claim 15 , wherein the template is tetrapropyl ammonium hydroxide and the porous silicate material is silver-incorporated silicalite.

17. The method of claim 15 , wherein the template is cetyltrimethyl ammonium bromide, and the porous silicate material is silver-incorporated mesosilicalite.

18. A method of treating cervical cancer, colorectal cancer, or both in a subject, comprising administering to the subject an effective amount of the medicinal nanocomposite of claim 1 .

19. An antibacterial composition, comprising the medicinal nanocomposite of claim 1 , the antibacterial composition having a minimum inhibitory concentration (MIC) of 0.1 to 3.5 milligram per milliliter (mg/ml) against a bacterial strain selected from the group consisting of Pseudomonas aeruginosa and Staphylococcus aureus.

20. A method of treating a bacterial infection in a subject, the method comprising administering to the subject an effective amount of the antibacterial composition of claim 19 .

Assignees

• Univ Imam Abdulrahman Bin Faisal

Inventors

• Jermy B Rabindran
• Ravinayagam Vijaya
• Rehman Suriya

Classifications

• A61K33/38 Primary

  Silver; Compounds thereof · CPC title

• A61K33/243 Primary

  Platinum; Compounds thereof · CPC title

• A61K47/02

  Inorganic compounds · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K9/143

  with inorganic compounds · CPC title